Trials / Completed
CompletedNCT01784536
Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Melinta Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Single-Dose IV Oritavancin Diphosphate | Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours. |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2013-02-06
- Last updated
- 2023-12-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01784536. Inclusion in this directory is not an endorsement.